The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. announced its participation as an attendee, sponsor, and exhibitor at the Parent Project Muscular Dystrophy 2026 Annual Conference, which will be held in Orlando from June 25 to 27.
The event will gather members of the Duchenne muscular dystrophy community to share experiences, discuss recent advancements, and explore emerging treatments for the disease. Solid Biosciences Inc. aims to engage stakeholders and highlight the company's commitment to supporting efforts toward new therapies.
View post on X Loading...
Earlier this year, Solid Biosciences presented clinical insights on its SGT-003 gene therapy candidate for Duchenne muscular dystrophy at a leading scientific congress (full article). The company has also outlined plans to connect with genetic medicine partners and discuss its platform and pipeline at BIO2026 in San Diego (full article). These activities reflect Solid Biosciences' ongoing engagement with the Duchenne muscular dystrophy research and business community.